EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and MEDICAL RESEARCH COUNCILExclusive License and Sponsored Research Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made effective the 31st day of October 2005 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Medical Research Council, a United Kingdom governmental institution having a place of business at 20 Park Crescent, London, United Kingdom, W1B 1AL (“MRC”).
EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and the UNIVERSITY OF LEICESTERExclusive License and Sponsored Research Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made effective the 10th day of June 2004 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and the University of Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United Kingdom (“Leicester”).
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This Commercial Supply Agreement (this “Agreement”) is made as of the 9th day of October, 2007 (the “Effective Date”) by and between Omeros Corporation, a Washington corporation, having its principal offices at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101 (“Omeros”), and Hospira Worldwide Inc., a Delaware corporation, having its principal offices at 275 North Field Drive, Lake Forest, Illinois 60045 (“Hospira”). Omeros and Hospira previously entered into a Master Development Agreement, dated May 8, 2007 (the “Development Agreement”), pertaining to the development of Omeros’ pharmaceutical drug product OMS103HP-S. Omeros and Hospira now desire to enter into an agreement for the commercial supply of OMS103HP-S by Hospira to Omeros. Therefore, in consideration of the mutual covenants and obligations set forth below, Omeros and Hospira (the “Parties” and each a “Party”) agree as follows:
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This agreement (the “Agreement”) is made effective the 23rd day of February 2009 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”).
OMEROS CORPORATION AGREEMENT FOR ANTIBODY DEVELOPMENTAgreement for Antibody Development • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This Agreement for Antibody Development (this “Agreement”) is between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and North Coast Biologics LLC (“North Coast”), a Washington Limited Liability Company having an address at 2815 Eastlake Avenue East, #300, Seattle, Washington 98102, and is effective as of October 31, 2008 (the “Effective Date”). Omeros and North Coast may be referred to herein each as a “Party” or together as the “Parties”.
AGREEMENT FOR ANTIBODY DISCOVERY AND DEVELOPMENTAgreement for Antibody Discovery and Development • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • California
This is an Agreement between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and Affitech AS (“Affitech”), having an address at Oslo Research Park, Gaustadalléen 21, N-0349 Oslo, Norway, and is effective as of July 25, 2008 (the “Effective Date”). Omeros and Affitech may be referred to herein each as a “Party” or together as the “Parties”.
SECOND AMENDMENT TO EXERCISE NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENTSRestricted Stock Purchase Agreements • September 16th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This Second Amendment to Exercise Notice and Restricted Stock Purchase Agreements (this “Agreement”) is made as of July 28, 2009 by and between Omeros Corporation, a Washington corporation (the “Company”), and Richard J. Klein (the “Purchaser”).
